EUCTR2007-005722-79-LT进行中（未招募）不适用
A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects who Fail the Combination Chemotherapy Only Arm. - PARTNER
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria
- •The following inclusion criteria must be met at the time of subject randomization.
- •Disease Related
- •Histologically or cytologically confirmed SCCHN or its variants (eg, basaloid
- •squamous cell carcinoma and adenosquamous cell carcinoma).
- •Primary tumor of the oropharynx, oral cavity, hypopharynx, or larynx, or SCCHN of unknown primary.
- •Diagnosis of metastatic disease and/or recurrent disease determined to be incurable by surgery or radiotherapy.
- •No prior systemic treatment for metastatic and/or recurrent SCCHN
- •Subjects who have received radiation as primary therapy are eligible if radiation
- •therapy treatment was completed > 4 weeks prior to randomization
- •Subjects who have previously received chemotherapy as part of the initial
- •multimodality treatment for locally advanced disease are eligible if the
- •chemotherapy was completed > 24 weeks prior to randomization
- •At least 1 unidimensionally measurable lesion of = 20 mm using conventional
- •techniques or =10 mm with spiral CT scan. Target lesions must not be chosen
- •from a previously irradiated field unless there had been documented tumor
- •progression in that lesion prior to randomization
- •Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1
- •at screening
- •Demographic
- •Men or women age = 18 years and < 70 years
- •Adequate hematologic data as follows (= 7 days before randomization):
- •- ANC = 1.5 x 109/L
- •- Platelet count = 100 x 109/L
- •- Hemoglobin = 9.0 g/dL
- •Adequate renal function (= 7 days before randomization):
- •- Adequate renal function with creatinine clearance = 60 mL/min calculated
- •by the Cockcroft-Gault method as follows:
- •- Male creatinine clearance = (140 - age) x (weight in kg) / (serum
- •- Female creatinine clearance = (140 - age) x (weight in kg) x 0.85 /
- •(serum Cr x 72)
- •Electrolyte function, as follows (= 7 days before randomization). If < lower limit of normal (LLN), subject may receive appropriate treatment and may be rescreened.
- •- Magnesium = LLN
- •- Calcium = LLN (If serum albumin is low, corrected calcium or ionized calcium should be = LLN)
- •- Potassium = LLN
- •Adequate hepatic function as determined by (= 7 days before randomization):
- •- Aspartate aminotransferase (AST) = 1.5 x upper limit of normal (ULN)
- •- Alanine aminotransferase (ALT) = 1.5 x ULN
- •- Alkaline phosphatase (ALK-P) = 2.5 x ULN
- •- Total bilirubin = ULN, unless attributed to Gilbert’s syndrome
- •Negative urine or serum pregnancy test = 72 hours prior to randomization
- •(females of childbearing potential only)
- •Before any non-standard of care study-specific procedure, subjects or their
- •legally acceptable representative must be able to comprehend and have signed
- •and dated the applicable independent ethics committee (IEC) or institutional
- •review board (IRB) approved written Informed Consent Form (ICF).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- 另有 2 项未显示
排除标准
- •Exclusion Criteria
- •Subjects who meet any of the following criteria at the time of randomization must be excluded from participation in this study.
- •Disease Related
- •Documented or symptomatic central nervous system (CNS) metastases
- •Nasopharyngeal carcinoma
- •History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or
- •evidence of interstitial lung disease on baseline chest computerized tomography
- •History of another primary cancer, except:
- •- Curatively treated in situ cervical cancer, or
- •- Curatively resected non-melanoma skin cancer or
- •- Other primary solid tumor curatively treated with no known active disease
- •present and no treatment administered for = 3 years prior to randomization
- •Clinically significant cardiovascular disease (including myocardial infarction,
- •unstable angina, symptomatic congestive heart failure, serious uncontrolled
- •cardiac arrhythmia) = 1 year of randomization
- •Subjects whose only site of metastatic disease is a single spiculated lung nodule
- •are assumed to have a second lung primary, and are excluded unless there is
- •unequivocal pathological confirmation of metastasis of the SCCHN primary
- •Pulmonary embolism, deep vein thrombosis, or other significant thromboembolic event = 8 weeks prior to randomization
- •Symptomatic peripheral neuropathy of Grade = 2 based on the CTCAE v3.0
- •(Symptomatic weakness and/ or sensory alteration or paresthesia (tingling) that
- •is interfering with function but not interfering with Activities of Daily Living
- •Subjects not recovered from all previous acute radiotherapy-related toxicities to = grade 1
- •History of severe skin disorder that in the opinion of the investigator may interfere with study conduct
- •Known positive test for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or chronic hepatitis B infection
- •Any co-morbid disease that would increase risk of toxicity
- •History of any medical, or psychiatric condition, or laboratory abnormality that in the opinion of the investigator may increase the risks associated with the studyparticipation, or may interfere with the interpretation of the results
- •Active infection requiring systemic treatment or any uncontrolled infection = 14 days prior to randomization
- •Hearing loss of Grade = 3 based on the CTCAE v3.0 Auditory/Ear (Hearing loss
- •requiring hearing aid or intervention (ie, interfering with ADL [without monitoring
- •Medications and Treatments
- •Known allergy or hypersensitivity to panitumumab, or other study medications.
- •Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment with small
- •molecule EGFr inhibitors (eg, gefitinib, erlotinib, lapatinib) unless received as
- •part of prior multimodality treatment (eg, as a radiation sensitizer) and completed > 24 weeks prior to randomization.
- •Subject is currently enrolled in or = 30 days since ending other investigational
- •device, investigational procedure, or drug study(s), or subject is receiving other
- •investigational agent(s)
- •Subjects requiring use of immunosuppressive agents (eg, methotrexate and cyclosporine), however, corticosteroids are allowed
- •Man or woman of child-bearing potential (women who are post-menopausal < 52
- •weeks, not surgically sterilized, or not abstinent) who do not consent to use
- •adequate contraceptive precautions (per institutional standard of care) during the
- •course of the study, a
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects who Fail the Combination Chemotherapy Only Arm.Cancer of the Head and NeckMedDRA version: 9.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2007-005722-79-ATAmgen Inc110
进行中（未招募）
1 期
A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects who Fail the Combination Chemotherapy Only Arm.Cancer of the Head and NeckMedDRA version: 9.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2007-005722-79-FRAmgen Inc113
进行中（未招募）
不适用
A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects who Fail the Combination Chemotherapy Only Arm.Cancer of the Head and NeckMedDRA version: 9.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2007-005722-79-CZAmgen Inc110
进行中（未招募）
1 期
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of ResponseCancer of the Head and NeckMedDRA version: 15.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 100000004864EUCTR2007-005722-79-BEAmgen Inc110
进行中（未招募）
不适用
A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects who Fail the Combination Chemotherapy Only Arm.---------------------------------------------------------------------------------------------------------Ensayo aleatorizado, abierto, controlado y de fase II de quimioterapia combinada con o sin Panitumumab como tratamiento de primera línea de sujetos con cáncer de cabeza y cuello metastásico o recurrente, y del cruce a Panitumumab en monoterapia como tratamiento de segunda línea en los sujetos del brazo de solo quimioterapia combinada cuyo tratamiento fracasa.Cancer of the Head and Neck.--------------------------------------------- Cáncer de cabeza y cuello.MedDRA version: 9.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2007-005722-79-ESAmgen Inc110